• Prakash A Patel, Julie A Wyrobek, Alexander J Butwick, Evan G Pivalizza, HareGregory M TGMTDepartment of Anesthesia, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada., C David Mazer, and Susan M Goobie.
• From the Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut.
• Anesth. Analg. 2022 Sep 1; 135 (3): 460-473.

AbstractTranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood loss and allogeneic red blood cell transfusion in several clinical settings. With a growing emphasis on patient blood management, TXA has become an integral aspect of perioperative blood conservation strategies. While clinical applications of TXA in the perioperative period are expanding, routine use in select clinical scenarios should be supported by evidence for efficacy. Furthermore, questions regarding optimal dosing without increased risk of adverse events such as thrombosis or seizures should be answered. Therefore, ongoing investigations into TXA utilization in cardiac surgery, obstetrics, acute trauma, orthopedic surgery, neurosurgery, pediatric surgery, and other perioperative settings continue. The aim of this review is to provide an update on the current applications and limitations of TXA use in the perioperative period.Copyright © 2022 International Anesthesia Research Society.

12 keywords...

hide…